EDSIVO™ Publications and Presentations

Journal of the American College of Cardiology 2019; 73:1948–57 – Frank – Peer Reviewed Publication

Audio summary by Editor-in-Chief of JACC, Dr. Valentin Fuster

Vascular Ehlers-Danlos Syndrome: Long-Term Observational Study



Lancet 2010; 376: 1476-84 – Ong – Peer Reviewed Publication

Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial


NORD Poster Presentation – Grabowsky – October 2018

Big Data Analytics to Estimate Prevalence of Ehlers-Danlos Syndrome

(Vascular Phenotype) and Rate of Rupture Events


Cardiology in Review 2017; 25: 247-253 – Nawarskas – Peer Reviewed Publication

Celiprolol, A Unique Selective Adrenoceptor Modulator


Genetics in Medicine 2014; 16(12): 881-8 – Pepin – Peer Reviewed Publication

Survival is affected by mutation type and molecular mechanism in vascular Ehlers–Danlos syndrome (EDS type IV)


Cardiovascular Research 2019; cvz095 – Dubacher – Peer Reviewed Publication

Celiprolol but not losartan improves the biomechanical integrity of the aorta in a mouse model of vascular Ehlers–Danlos syndrome